Characterizing BASE and HER2 for use as tumor markers for breast cancer

表征 BASE 和 HER2 作为乳腺癌肿瘤标志物的用途

基本信息

批准号：
7465332
负责人：
Kristi Egland
金额：
$ 13.79万
依托单位：
UNIVERSITY OF SOUTH DAKOTA
依托单位国家：
美国
项目类别：
财政年份：
资助国家：
美国
起止时间：
至
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/7465332
关键词：
American Indians Amino Acid Sequence BRCA1 gene BRCA2 gene Brain Breast Cancer Cell Breast Cancer Early Detection Cancer Patient Cancer cell line Clinical Diagnosis Diagnostic Disease ERBB2 gene Early Diagnosis Estrogen Receptors Female Foundations Frequencies Future Genes Goals Health Housekeeping Kidney Knowledge Liver Localized Lung Malignant Neoplasms Mammary Gland Parenchyma Mammary gland Membrane Messenger RNA Molecular Muscle Native Americans Neoplasm Metastasis Organ Patients Peptide Signal Sequences Pilot Projects Population Procedures Progesterone Receptors Protein Overexpression Proteins RNA Relative (related person)Research Research Project Grants Salivary Glands Sampling Screening procedure Skin Cancer South Dakota Tissues Tumor Markers Virulence Woman base cDNA Library malignant breast neoplasm novel programs tool tumor tumorigenesis

项目摘要

The overall goals of the research project administered through the South Dakota Health Research Foundation are to define the frequency of breast cancers from American Indian patients that express a novel tumor marker designated BASE and to investigate overexpression of HER2 in breast cancers isolated from American Indian females. This information will determine whether BASE and HER2 are useful breast cancer tumor markers in American Indians. This research will explore the presence of a newly discovered tumor marker, BASE, and amplification of a clinically validated marker, HER2, in breast cancers from Native American women. The knowledge gained from this proposal will advance our understanding of whether BASE could be used as a tumor marker for breast cancer in American Indian women. In addition, we will begin to determine the status of HER2 overexpression in breast cancers from American Indians. In order to accomplish these goals, I propose the following specific aims: Specific Aim 1. Determine frequency and types of breast cancers from American Indian women that express BASE. Specific Aim 2. Investigate the status of HER2 amplification in breast cancers from American Indian women. One long-term goal of this research program is to validate whether the Esr1, Pgr, BRCA1, BRCA2 and the extent of HER2 amplifications accurately predict treatment and overall survival of American Indian females with breast cancer. This pilot project will give us the opportunity to begin to investigate the status of HER2 amplification in American Indian breast cancers. In the future, it will also be necessary to analyze the status of the Esr1 and Pgr in the same samples.

由南达科他州健康研究基金会管理的该研究项目的总体目标是确定表达一种名为 BASE 的新型肿瘤标记物的美洲印第安人患者患乳腺癌的频率，并研究从美洲印第安人女性中分离出的乳腺癌中 HER2 的过度表达。该信息将确定 BASE 和 HER2 是否是美洲印第安人中有用的乳腺癌肿瘤标志物。这项研究将探索美国原住民女性乳腺癌中新发现的肿瘤标记物 BASE 的存在以及临床验证标记物 HER2 的扩增。从该提案中获得的知识将加深我们对以下问题的理解： BASE 可用作美洲印第安女性乳腺癌的肿瘤标志物。此外，我们将开始确定美洲印第安人乳腺癌中 HER2 过度表达的状况。为了实现这些目标，我提出以下具体目标：具体目标 1. 确定表达 BASE 的美洲印第安女性乳腺癌的频率和类型。具体目标 2. 研究美洲印第安女性乳腺癌中 HER2 扩增的状况。该研究计划的一个长期目标是验证 Esr1、Pgr、BRCA1、BRCA2 和 HER2 扩增的程度是否能够准确预测美洲印第安女性乳腺癌患者的治疗和总体生存率。该试点项目将使我们有机会开始研究美洲印第安人乳腺癌中 HER2 扩增的状况。未来还需要分析同一样本中Esr1和Pgr的状态。